Sebaceous Gland Hyperplasia (Sebaceous Hyperplasia, Senile Sebaceous Hyperplasia)
Are You Confident of the Diagnosis?
Sebaceous hyperplasia (SH) is a common condition that primarily affects middle aged to elderly patients and increases in frequency with age. Although SH can be seen in neonates it is considered to be physiologic rather than pathologic. SH may be single or multiple in number and the most common locations are the forehead, cheeks and nose (
Sebaceous hyperplasia. Yellow lobulated papule with central dell on forehead.
There are several special variants noted in the literature including presenile hereditary sebaceous hyperplasia, juxtaclavicular beaded lines, giant sebaceous hyperplasia, and linear sebaceous hyperplasia. Rhinophyma (a variant of rosacea) is also characterized in its earliest form by sebaceous hyperplasia.
Characteristic findings on physical examination
Expected results of diagnostic studies
On physical examination, SH presents as a yellow white lobulated papule, often umbilicated at the central ostium/pore. On dermoscopy there are “crown vessels” that wind over the top of the yellow lobules, which are rarely branching and do not cross the center of the lesion (
Dermoscopic view of sebaceous hyperplasia with obvious yellow lobulated papule with vessels coursing over crown but not across center of lesion.
The diagnosis of sebaceous hyperplasia is made clinically. If the diagnosis is questionable, a shave or punch biopsy can be done.
A biopsy is generally done to rule out a basal cell carcinoma or other sebaceous neoplasm. Dermoscopically (
Histologically SH is characterized by 1 to 2 layers of germinative basaloid cells surrounding mature sebocytes. Several lobules empty into a single follicular infundibulum. Only one gland is hypertrophied; surrounding glands are normal, which would classify it most accurately as a hamartoma.
Who is at Risk for Developing this Disease?
Sebaceous glands are found in association with hair follicles. There are areas commonly known to have ectopic sebaceous glands (unassociated with hair follicles) including the vermilion border of the lip (Fordyce spots), areola (Montgomery’s tubercles), labia minora, prepuce and mucosa of penis (Tyson glands). SH can occur in any of these locations and the biggest risk factor is increasing age. By mean age of 51 the incidence in several studies has been around 1% increasing to 26% by the mean age of 82.
There is a hereditary form passed in autosomal dominant fashion with onset during puberty that is found on the neck and trunk in addition to the face. Transplant patients on cyclosporine for immunosuppression have a higher incidence of SH as well. Furthermore, those transplant patients that develop SH are also at higher risk for non-melanoma skin cancer.
There is also a single case report of a patient who developed SH shortly after starting HAART (Highly Active Antiretroviral Therapy) for HIV. There is question whether these cases are effects of immunosuppression or medication direct effects. Cyclosporine is known to have direct effects on pilosebaceous glands with induction of acne and hypertrichosis.
What is the Cause of the Disease?
The cause of sebaceous hyperplasia is unknown but likely develops as a consequence of aging, ultraviolet radiation, and immunosuppression or direct effect of medication.
Systemic Implications and Complications
Sebaceous hyperplasia can be associated with Muir-Torre syndrome; however, sebaceous hyperplasia is common and Muir-Torre syndrome rare. Therefore, in a patient with sebaceous hyperplasia, no further investigation for Muir-Torre syndrome is warranted unless there is a family or personal history of colon cancer or sebaceous adenomas. Examination via immunohistochemical staining with MLH-1 and MSH-2 may be used to look at microsatellite instability.
Sebaceous hyperplasia is a cosmetic concern and therefore no treatment is needed. The risks and benefits of treatment must be understood and discussed with the patient. Treatment options are summarized in the
Treatment options for sebaceous hyperplasia
|Topical||Hyfercation chemical peel (focal or diffuse)||Cryosurgery|
|- Long-term topical retinoids||Curretage|
|Systemic: For hereditary or widespread disfiguring disease||Photodynamic terapy||Shave removal|
|- Isotretinoin||Laser (PDL, IPL, Diode, CO2)|
Optimal Therapeutic Approach for this Disease
Patients with sebaceous hyperplasia do not need treatment. Reassurance that the lesion is benign often suffices. If the patient desires removal or treatment for cosmetic reasons, there are multiple options as noted in the
Our approach is to start slowly for 6 months with tretinoin 0.025% cream and increase to tretinoin 0.05% over time. Consistency rather than strength may be better, though there is no study to validate that approach. Light hyfercation, cryotherapy, curretage, focal chemical peels.
Because salicylic acid is lipophilic, our preferred peel is a Jessner’s peel. These modalities are ideal for single or few lesions. For more widespread disease, photodynamic therapy, PDL and IPL (with or without aminolevulenic acid) are low risk options. They may require several treatments.
CO2 laser has been used in the literature, but is higher risk and similar long-term outcome with recurrence are still possible. Oral isotretinoin can be used and is effective. Due to the risk/ benefit association the authors would consider low-dose isotretinoin of 20 to 40mg daily, mostly at the lower range. None of the studies have long-term follow-up to know whether there is lasting remission with treatment. There are several cases that recurred after short-term isotretinoin courses. This would be the last resort for widespread or disfiguring disease because the risk of treatment outweighs the benefit in most cases.
No long-term management or follow-up care is needed for sebaceous hyperplasia.
Unusual Clinical Scenarios to Consider in Patient Management
There are several special variants noted in the literature including presenile hereditary sebaceous hyperplasia, juxtaclavicular beaded lines, giant sebaceous hyperplasia, and linear sebaceous hyperplasia.
What is the Evidence?
Eisen, DB, Michael, DJ. "Sebaceous lesions and their associated syndromes: Part I". J Am Acad Dermatol. vol. 61. 2009. pp. 549-60.
Eisen, DB, Michael, DJ. "Sebaceous lesions and their associated syndromes: Part II". J Am Acad Dermatol. vol. 61. 2009. pp. 563-78.(The first two are CME articles out of the JAAD that discuss sebaceous hyperplasia and other sebaceous lesions encountered in dermatology. They discuss the importance of recognizing sebaceous lesions, especially sebaceous adenoma and sebaceous carcinoma. The association with Muir-Torre is discussed, the pathologic stains MLH1/MSH2 for microsatellite instability and the need to screen for visceral malignancy.)
Zalaudek, I, Kreusch, J, Giacomel, J, Ferrara, G, Catriciala, C, Argenziano, G. "How to diagnose nonpigmented skin tumors: A review of vascular structures seen with dermoscopy, Part II". J Am Acad Dermatol. vol. 63. 2010. pp. 377-86.
Zaballos, P, Ara, M, Puig, S, Malvehy, J. "Dermoscopy of sebaceous hyperplasia". Arch Dermatol. vol. 141. 2005. pp. 808.(The preceding two articles discuss the dermoscopy diagnosis of sebaceous hyperplasia. Dermoscopy is an increasingly valuable tool used in the clincal diagnosis of skin lesions, and this is a good guide for the diagnosis of nonpigmented skin lesions and sebaceous hyperplasia.)
Richey, DF. "Aminolevulinic acid photodynamic therapy for sebaceous gland hyperplasia". Dermatol Clin. vol. 25. 2007. pp. 59-65.(This paper reviews five articles in the use of ALA/PDT for sebaceous hyperplasia. The recommended incubation time is 1 hour to activate the ALA-induced PpIX with (in order of author’s preference) PDL, blue/IPL, yellow, and red light.)
Short, KA, Williams, A, Creamer, D, Fuller, LC. "Sebaceous gland hyperplasia, human immunodeficiency virus and highly active anti-retroviral therapy". Clin Exp Dermatol. vol. 33. 2008. pp. 354-5.(Interesting case report of the induction of sebaceous hyerplasia after the start of HAART for HIV.)
Ferahbas, A, Utas, S, Akcakus, M, Gunes, T, Mistik, S. "Prevalence of cutaneous findings in hospitalized neonates: a prospective observational study". Pediatr Dermatol. vol. 26. 2009. pp. 139-42.(This prospective study discusses the most common skin findings found in Turkish neonates. Approximately 32% had sebaceous hyperplasia, which resolves and is physiologic rather than pathologic.)
Grimalt, R, Ferrando, J, Mascaro, JM. "Premature familial sebaceous hyperplasia: Successful response to oral isotretinoin in three patienits". J Am Acad Dermatol. vol. 36. 1997. pp. 120-2.(Three patients with progressive early onset disfiguring sebaceous hyperplasia were treated with isotretinoin 1mg/kg daily with good response, although long-term outcome is unknown. One was maintained on an every-other-day dose of 20mg for an extended period and others on topical retinoids.)
Bader, RS, Scarborough, DA. "Surgical Pearl: intralesional electrodesiccation of sebaceous hyperplasia". J Am Acad Dermatol. vol. 42. 2000. pp. 127-8.(The article describes the use of intralesional electrodessication at setting of 20 after local anesthetic with good results and lack of recurrence up to 7 months out from procedure for the treatment of sebaceous hyperplasia.)
Salim, A, Reece, SM, Smith, AG, Harrison, D, Ramsay, HM, Harden, PN. "Sebaceous hyperplasia and skin cancer in patients undergoing renal transplant". J Am Acad Dermatol. vol. 55. 2006. pp. 878-81.(This article highlights the association of sebaceous hyperplasia in renal transplants with the higher risk of nonmelanoma skin cancer compared with those transplant patients without sebaceous hyperplasia.)
Copyright © 2017, 2012 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC